Goodwin Advises Tubulis on Exclusive Option and License Agreement With Gilead to Develop ADC Candidate for Select Solid Tumor Target for $20 Million Upfront and Up to $445 Million in Additional Payments
December 04, 2024
December 04, 2024
BOSTON, Massachusetts, Dec. 4 -- Goodwin, a law firm, issued the following news release:
The Life Sciences team advised Tubulis on an exclusive option and license agreement to discover and develop an antibody-drug conjugate (ADC) against a solid tumor target with Gilead. Under the terms of the agreement, Tubulis will receive an upfront payment of $20 million and, if Gilead exercises its option, a separate option exercise fee of $30 million.
In addition, Tubulis will be . . .
The Life Sciences team advised Tubulis on an exclusive option and license agreement to discover and develop an antibody-drug conjugate (ADC) against a solid tumor target with Gilead. Under the terms of the agreement, Tubulis will receive an upfront payment of $20 million and, if Gilead exercises its option, a separate option exercise fee of $30 million.
In addition, Tubulis will be . . .